← 返回专利悬崖列表
Sarconeos
Tier C · 观察 / 贸易Sarconeos
Biophytis
原研
-
首批上市
-
到期年（公开口径）
无销量数据
峰值销售
化学药
类型
靶点：MAS
商品名：Sarconeos
适应症（已批准）：肌肉减少症、超重、肥胖症、肌肉萎缩、杜氏肌营养不良症
各地区研发/上市状态
美国
临床申请
2024-06-10
欧盟
临床三期
2023-05-15
中国
-
日本
-
合成路线与中间体1 routes
原研路线 × 1优化路线（非专利）× 0工艺路线 × 0
路线按「原研路线 → 优化路线 / 工艺路线（非专利）」排序。每条路线附本站自绘的路线流程图（中间体 → 原料药）与中间体表（编号 / CAS / 英文名），可直接用于供应商开发与询价。流程图由本站依据已授权的结构化数据自行渲染，未使用任何第三方路线图。
原研Route 1步骤 10 · 总收率 6.0 mg (BIO-101)
BIO-101-00127948-74-9BIO-101-002264925-82-8BIO-101-003264925-83-9BIO-101-004264925-84-0BIO-101-005264925-85-1BIO-101-006264925-86-2BIO-101-007264925-87-3BIO-101-008264925-88-4BIO-101-009264925-89-5BIO-101-01054594-70-6BIO-1015289-74-7API · Sarconeos
| 编号 | CAS 号 | 中间体名称 |
|---|---|---|
| BIO-101-001 | 27948-74-9 | (6R,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-4,5,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-6-ol |
| BIO-101-002 | 264925-82-8 | 2-(((6R,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-4,5,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-6-yl)oxy)tetrahydro-2H-pyran |
| BIO-101-003 | 264925-83-9 | (1R,3aS,3bS,5R,6aS,7aR,8aR,8bS,10aR)-8a,10a-dimethyl-1-((R)-6-methylheptan-2-yl)-5-((tetrahydro-2H-pyran-2-yl)oxy)hexadecahydro-1H-cyclopenta[7,8]phenanthro[2,3-b]oxirene |
| BIO-101-004 | 264925-84-0 | (2S,3R,6R,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-6-((tetrahydro-2H-pyran-2-yl)oxy)hexadecahydro-1H-cyclopenta[a]phenanthren-2-d-3-ol |
| BIO-101-005 | 264925-85-1 | (2S,6R,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-6-((tetrahydro-2H-pyran-2-yl)oxy)hexadecahydro-3H-cyclopenta[a]phenanthren-3-one-2-d |
| BIO-101-006 | 264925-86-2 | (2S,3S,6R,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-6-((tetrahydro-2H-pyran-2-yl)oxy)hexadecahydro-1H-cyclopenta[a]phenanthren-2-d-3-ol |
| BIO-101-007 | 264925-87-3 | (2S,3S,6R,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-6-((tetrahydro-2H-pyran-2-yl)oxy)hexadecahydro-1H-cyclopenta[a]phenanthren-3-yl-2-d acetate |
| BIO-101-008 | 264925-88-4 | (2S,3S,6R,8S,9S,10R,13R,14S,17R)-6-hydroxy-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)hexadecahydro-1H-cyclopenta[a]phenanthren-3-yl-2-d acetate |
| BIO-101-009 | 264925-89-5 | (2S,3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl-2-d acetate |
| BIO-101-010 | 54594-70-6 | (2S,3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-2-d-3-ol |
| BIO-101 | 5289-74-7 | (2S,3R,5R,9R,10R,13R,14S,17S)-2,3,14-trihydroxy-10,13-dimethyl-17-((2R,3R)-2,3,6-trihydroxy-6-methylheptan-2-yl)-1,2,3,4,5,9,10,11,12,13,14,15,16,17-tetradecahydro-6H-cyclopenta[a]phenanthren-6-one |
常见问题（FAQ）
Sarconeos的适应症有哪些？
已批准的适应症包括：肌肉减少症、超重、肥胖症、肌肉萎缩、杜氏肌营养不良症。
Sarconeos的专利什么时候到期？
Sarconeos的专利到期年暂无公开口径，本页会在数据管道核实后更新。
Sarconeos有几条合成路线？
本站收录 1 条合成路线，最短路线 10 步、总收率 6.0 mg (BIO-101)。每条路线的中间体均带登记编号与 CAS 号。
Sarconeos的关键中间体在哪里可以采购？
Sarconeos路线中的中间体均已建立 CAS 档案，可直接按 CAS 发起询价，需求会进入供应网络撮合池。
如何获取Sarconeos中间体的报价？
在本页选择目标中间体的 CAS 进入档案页，或在询价页直接提交需求；CAS 会自动带入供需撮合流程，由供应网络反馈报价。
数据来源：多源数据交叉核实（仅结构化字段） · 2026-10-03